Filing Flows › Travere Therapeutics (TVTX) › How it makes money
How Travere Therapeutics (TVTX) makes money
Travere Therapeutics (TVTX) made $225M of revenue in the third quarter 2026 (Q3 2026), +36% from a year earlier. Total net product sales brought in $220M (98%); License and collaboration revenue brought in $4.4M (2%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Total net product sales | $220M | 98.1% | +36% | +95% |
| ↳ FILSPARI | $200M | 89.1% | +42% | +120% |
| ↳ Tiopronin products | $20.0M | 8.9% | -1% | -10% |
| License and collaboration revenue | $4.4M | 1.9% | -47% | -92% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $225M | 100.0% |
| Operating cash flow | $98.2M | 43.7% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $225M | +36% |
| Q2 2026 | $170M | +48% |
| Q1 2026 | $127M | +56% |
| Q4 2025 | $130M | +73% |
| Q3 2025 | $165M | +162% |
| Q2 2025 | $114M | +112% |
| Q1 2025 | $81.7M | +98% |
From Travere Therapeutics' 10-Q filed Nov 2, 2026 (on EDGAR).
Questions
How does Travere Therapeutics make money?
Travere Therapeutics (TVTX) made $225M of revenue in the third quarter 2026 (Q3 2026), +36% from a year earlier. Total net product sales brought in $220M (98%); License and collaboration revenue brought in $4.4M (2%).
What is Travere Therapeutics' biggest business?
Total net product sales: $220M in the third quarter 2026, 98% of revenue, +95% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.